Showing results (121-130 of 132) with videos related to
Sort By:
Pageof 14
Clinical Nutrition (Edinburgh, Scotland)|May 16, 2006
ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantationA Weimann, M Braga, L Harsanyi, et al.Acta Haematologica|February 29, 2000
Efficacy of further attempts to mobilize CD34+ peripheral stem cells with alternative procedures after primary failureN Kröger, C Rauhöft, W Zeller, et al.Journal of Hepatology|February 24, 2007
HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administrationJens Rosenau, Therese Kreutz, Matthias Kujawa, et al.Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.Bone Marrow Transplantation|October 24, 2000
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemiaN Kröger, T Zabelina, S Sonnenberg, et al.Bone Marrow Transplantation|January 7, 1999
Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemiaN Kröger, W Krüger, G Wacker-Backhaus, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 1999
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remissionA R Zander, C Berger, N Kröger, et al.British Journal of Haematology|September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupM Hallek, B Schmitt, M Wilhelm, et al.Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.Pageof 14